Content area
Abstract
Depression rates have risen globally during the COVID-19 pandemic. While social support is a known protective factor, more research is needed to quantify the extent to which social support could reduce depression risk during a global crisis and identify which types of support are most helpful and for whom. We analysed longitudinal data from 69,066 participants in the All of Us Research Program who completed COVID-19 Participant Experience surveys between May and July 2020, including measures of perceived social support and depressive symptoms. Using mixed-effects logistic regression models, we tested associations between social support (overall and its subtypes) and elevated depressive symptoms, and assessed potential effect modifiers. Approximately 16% of participants experienced elevated depressive symptoms. Overall social support was associated with a 55% lower odds of depression. Emotional/informational support and positive social interactions showed strongest protective associations with depression, followed by tangible support. Combinations of support subtypes showed a dose–response gradient, with higher levels across all three subtypes linked to over a sixfold reduction in depression odds. Significant effect modifiers included sex, age, pre-pandemic mood disorder and pandemic-related financial stressors. Enhanced social support across multiple domains could benefit individuals with higher risks for depression, supporting a precision prevention approach.
Using data from a large US population survey, Choi et al. investigated the nuanced associations between perceived social support and the risk for depression during the COVID-19 pandemic.
Details
; Lee, Younga H. 2 ; Liu, Zhaowen 2 ; Fatori, Daniel 3 ; Bauermeister, Joshua R. 4 ; Luh, Rebecca A. 5 ; Clark, Cheryl R. 6 ; Brunoni, André R. 3 ; Bauermeister, Sarah 4 ; Smoller, Jordan W. 1 1 Massachusetts General Hospital, Center for Precision Psychiatry, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts General Hospital, Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Harvard Medical School, Department of Psychiatry, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Broad Institute of MIT and Harvard, Stanley Center for Psychiatric Research, Boston, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623)
2 Massachusetts General Hospital, Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Harvard Medical School, Department of Psychiatry, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Broad Institute of MIT and Harvard, Stanley Center for Psychiatric Research, Boston, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623)
3 Faculdade de Medicina da Universidade de São Paulo, Departamento de Psiquiatria, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
4 University of Oxford, Department of Psychiatry, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
5 Massachusetts General Hospital, Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
6 Brigham and Women’s Hospital, Division of General Internal Medicine and Primary Care, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294)




